Skip to content

Moxibustion for treating cancer-related fatigue: a clinical trial

Moxibustion for treating cancer-related fatigue: a multicenter, assessor-blinded, randomized controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002170
Enrollment
96
Registered
2016-12-16
Start date
2016-12-30
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Participants will be randomly assigned to one of the three groups: moxibustion treatment, sham moxibustion, or usual care group. The two former groups will receive moxibustion treatme

Sponsors

Korea Institute of Oriental Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both male and female, aged 19 or over, but under 80 years 2. Cessation of cancer-related treatments (e.g. surgery, chemotherapy, radiotherapy, immunotherapy, except for on-going hormone therapy, which must have been initiated at least 3 weeks prior to enrollment) at least 12 weeks before the trial 3. Continuous fatigue related to cancer treatment or cancer itself for at least 4 weeks, fulfilment of The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic criteria for cancer-related fatigue, and 4 and higher points in a Brief Fatigue Inventory (BFI) score 4. The Eastern Cooperative Oncology Group (ECOG) performance status = 2 5. Willingness to participate in the trial and provide written consent

Exclusion criteria

Exclusion criteria: 1. Current level of fatigue even before the diagnosis of cancer 2. Severe anemia (platelet count 10,000/µL 6. Abnormal findings in thyroid function test (abnormal level of Free thyroxine [free T4] and thyroid stimulating hormone [TSH] 5.1 uIU/ml) 7. Abnormal findings in liver function test or renal function test, or serious liver failure or renal failure (aspartate aminotransferase or alanine aminotransferase = 2 x upper normal range, or creatinine = 2.0 mg/dL) 8. A score of 11 points and over in subscale of anxiety or depression in Hospital Anxiety and Depression Scale (HADS) 9. A score of 15 points and over in insomnia severity index (ISI) 10. Level of cancer pain measured by numeric rating scale = 4 11. Six months or less life expectancy 12. A plan of surgery, chemotherapy, radiotherapy during the study 13. Past history of medication (methylphenidate, modafinil, bupropion, dexamethasone) to manage cancer-related fatigue at least 4 weeks before the trial 14. Past history of Korean medical treatment (e.g. acupuncture, moxibustion, cupping, or herbal medicine, etc.) to manage cancer-related fatigue at least 4 weeks before the trial 15. Past history in the preivous 4 weeks or a new plan during the study of initiating dietary supplements or non-pharmacologic therapies (e.g. cognitive behavioral therapy, exercise etc.) to alleviate cancer-related fatigue 16. Having participated in other clinical trial in the precious 4 weeks 17. Past history of hypersensitivity reactions or serious adverse reactions after moxibustion treatment or an inability to cooperate with moxibustion treatment due to some reasons such as dyspnea 18. Women who are pregnant, lactating, or planning to become pregnant 19. Presence of other apparent factors or any diseases that could cause the current fatigue other than cancer treatment or cancer itself

Design outcomes

Primary

MeasureTime frame
Mean change of total scores in the Brief fatigue inventory (BFI)

Secondary

MeasureTime frame
Mean change of total scores in the BFI;Mean change of total scores in the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) ;Mean change of total scores in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30);Mean change of total scores in the Korean version of Montreal Cognitive Assessment (MoCA-K);Adverse event;Blinding test;Credibility questionnaire

Countries

Korea, Republic of

Contacts

Public ContactJung-hyo Cho

Daejeon Korean Medicine Hospital of Daejeon University

choajoa@dju.kr+82-42-229-6806

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 9, 2026